[
  {
    "Company": "Aardvark",
    "COUNTRY": "US",
    "Indication": "Prader-Willi Syndrome",
    "TherapeuticArea1": "Endocrinology",
    "TherapeuticArea2": "Genetic",
    "Candidate": "ARD-101",
    "Class1": "Anti-inflammatories",
    "Class2": "Obesity",
    "Class3": "Small molecules",
    "MOA": "G protein-coupled receptor agonists",
    "RPDD Month": "8",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 2",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Advent",
    "COUNTRY": "US",
    "Indication": "Bronchopulmonary Dysplasia",
    "TherapeuticArea1": "Pulmonology",
    "TherapeuticArea2": "Neonatology",
    "Candidate": "Vitamin A palmitate",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "7",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Arcturus",
    "COUNTRY": "US",
    "Indication": "Cystic Fibrosis",
    "TherapeuticArea1": "Pulmonology",
    "TherapeuticArea2": "Genetic",
    "Candidate": "ARCT-032",
    "Class1": "Antifibrotics",
    "Class2": "RNA",
    "Class3": "",
    "MOA": "Cystic fibrosis transmembrane conductance regulator expression stimulants",
    "RPDD Month": "11",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 1b",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Arcturus",
    "COUNTRY": "US",
    "Indication": "Ornithine Transcarbamylase Deficiency",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Candidate": "ARCT-810",
    "Class1": "RNA",
    "Class2": "",
    "Class3": "",
    "MOA": "Ornithine carbamoyltransferase expression stimulants",
    "RPDD Month": "11",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 1b",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "AUM",
    "COUNTRY": "SG",
    "Indication": "Neuroblastoma",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Candidate": "AUM302",
    "Class1": "2 ring heterocyclic compounds",
    "Class2": "Antineoplastics",
    "Class3": "Aza compounds",
    "MOA": "1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors; PIM3 protein inhibitors; Proto oncogene protein c pim 1 inhibitors; Proto-oncogene protein pim-2 inhibitors",
    "RPDD Month": "1",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Bloom Science",
    "COUNTRY": "US",
    "Indication": "Dravet Syndrome",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Candidate": "BL-001",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "8",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 1",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Bloomsbury Genetic",
    "COUNTRY": "UK",
    "Indication": "Dopamine Transporter Deficiency Syndrome",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Candidate": "BGT-DTDS",
    "Class1": "AAV",
    "Class2": "AAV2",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "8",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Bloomsbury Genetic",
    "COUNTRY": "UK",
    "Indication": "Ornithine Transcarbamylase Deficiency",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Candidate": "BGT-OTCD",
    "Class1": "AAV",
    "Class2": "AAV2",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "8",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 1/2",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Bloomsbury Genetic",
    "COUNTRY": "UK",
    "Indication": "Infantile Neuroaxonal Dystrophy",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Candidate": "BGT-INAD",
    "Class1": "AAV",
    "Class2": "AAV2",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "8",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Bloomsbury Genetic",
    "COUNTRY": "UK",
    "Indication": "Niemann-Pick Disease Type C",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "Metabolic",
    "Candidate": "BGT-NPC",
    "Class1": "AAV",
    "Class2": "AAV9",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "8",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Daiichi Sankyo",
    "COUNTRY": "JP",
    "Indication": "Netherton Syndrome",
    "TherapeuticArea1": "Dermatology",
    "TherapeuticArea2": "Genetic",
    "Candidate": "DS-2325",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "5",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 1",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Dyne",
    "COUNTRY": "US",
    "Indication": "Duchenne Muscular Dystrophy",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Candidate": "DYNE-251",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "5",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 1/2",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Edgewise",
    "COUNTRY": "US",
    "Indication": "Duchenne Muscular Dystrophy",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Candidate": "EDG-5506",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "11",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 2",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Elastrin",
    "COUNTRY": "US",
    "Indication": "Generalized Arterial Calcification of Infancy",
    "TherapeuticArea1": "Cardiovascular",
    "TherapeuticArea2": "",
    "Candidate": "ELT-001",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "10",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "FLAG",
    "COUNTRY": "US",
    "Indication": "Diffuse Intrinsic Pontine Glioma",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Candidate": "FLAG-003",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "2",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "GC",
    "COUNTRY": "KR",
    "Indication": "Sanfilippo Syndrome A",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "Metabolic",
    "Candidate": "GC1130A",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "1",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Gut-Brain-Axis",
    "COUNTRY": "US",
    "Indication": "Pitt-Hopkins Syndrome",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "Genetic",
    "Candidate": "Microbiota Transplant Therapy",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "8",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 2",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "HuidaGene",
    "COUNTRY": "CN",
    "Indication": "Duchenne Muscular Dystrophy",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Candidate": "HG302",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "12",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "HuidaGene",
    "COUNTRY": "CN",
    "Indication": "MECP2 duplication syndrome",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "Genetic",
    "Candidate": "HG204",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "8",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "HuidaGene",
    "COUNTRY": "CN",
    "Indication": "RPE65 mutations inherited retinal disease",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "Genetic",
    "Candidate": "HG004",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "8",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 1",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Ionis",
    "COUNTRY": "US",
    "Indication": "Pelizaeus-Merzbacher Disease",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "Genetic",
    "Candidate": "ION356",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "10",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "JCR",
    "COUNTRY": "JP",
    "Indication": "Mucopolysaccharidosis Type II",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Candidate": "JR-141",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "1",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 3",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Lactiga US",
    "COUNTRY": "US",
    "Indication": "Common Variable Immunodeficiency",
    "TherapeuticArea1": "Immunology",
    "TherapeuticArea2": "",
    "Candidate": "LCTG-001",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "8",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Laminar",
    "COUNTRY": "SP",
    "Indication": "Pediatric-Type Diffuse High Grade Glioma",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Candidate": "LAM561",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "9",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 1",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Myopax",
    "COUNTRY": "DE",
    "Indication": "Exstrophy-Epispadias Complex",
    "TherapeuticArea1": "Urology",
    "TherapeuticArea2": "",
    "Candidate": "Stem Cell Therapy",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "7",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "NorthSea",
    "COUNTRY": "NL",
    "Indication": "Intestinal Failure-Associated Liver Disease",
    "TherapeuticArea1": "Gastroenterology",
    "TherapeuticArea2": "Hepatology",
    "Candidate": "SEFA-6179",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "10",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 2a",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Ocugen",
    "COUNTRY": "US",
    "Indication": "Stargardt Disease",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "Genetic",
    "Candidate": "OCU410ST",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "4",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 1/2",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Orphagen",
    "COUNTRY": "US",
    "Indication": "Adrenocortical Carcinoma",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Candidate": "OR-449",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "1",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Satellos",
    "COUNTRY": "CA",
    "Indication": "Duchenne Muscular Dystrophy",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Candidate": "SAT-3153",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "8",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Sernova",
    "COUNTRY": "CA",
    "Indication": "Hemophilia Type A",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Candidate": "Cell Pouch",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "11",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "SiSaf",
    "COUNTRY": "UK",
    "Indication": "Osteopetrosis",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "Metabolic",
    "Candidate": "SIS-101-ADO",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "5",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "SpringWorks",
    "COUNTRY": "US",
    "Indication": "Neurofibromatosis type 1-associated Plexiform Neurofibromas",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "Neurology",
    "Candidate": "mirdametinib",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "11",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 2b",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Sumitomo",
    "COUNTRY": "JP",
    "Indication": "Ewing's Sarcoma",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Candidate": "TP-1287",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "4",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 1",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "SynaptixBio",
    "COUNTRY": "UK",
    "Indication": "TUBB4A Leukodystrophy",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Candidate": "TBD",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "2",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Synlogic",
    "COUNTRY": "US",
    "Indication": "Phenylketonuria",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Candidate": "labafenogene marselecobac (SYNB1934)",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "1",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 3",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Takeda",
    "COUNTRY": "JP",
    "Indication": "Congenital Thrombotic Thrombocytopenic Purpura",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Candidate": "ADZYNMA",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "8",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 3",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "Approved",
    "FDA Marketing Approval Month": "11",
    "FDA Marketing Approval Year": "2023",
    "Competitors": "",
    "PRV Issue Month": "1",
    "PRV Issue Year": "2024",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Tetra (Shionogi)",
    "COUNTRY": "JP",
    "Indication": "Fragile X Syndrome",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "Genetic",
    "Candidate": "zatolmilast",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "9",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "N",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Alnylym Pharmaceuticals",
    "COUNTRY": "US",
    "Indication": "Prader-Willi Syndrome",
    "TherapeuticArea1": "Endocrinology",
    "TherapeuticArea2": "Genetic",
    "Candidate": "ARD-101",
    "Class1": "Anti-inflammatories",
    "Class2": "Obesity",
    "Class3": "Small molecules",
    "MOA": "G protein-coupled receptor agonists",
    "RPDD Month": "8",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 2",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Amryt Pharmaceuticals",
    "COUNTRY": "US",
    "Indication": "Bronchopulmonary Dysplasia",
    "TherapeuticArea1": "Pulmonology",
    "TherapeuticArea2": "Neonatology",
    "Candidate": "Vitamin A palmitate",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "7",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "AstraZeneca",
    "COUNTRY": "US",
    "Indication": "Cystic Fibrosis",
    "TherapeuticArea1": "Pulmonology",
    "TherapeuticArea2": "Genetic",
    "Candidate": "ARCT-032",
    "Class1": "Antifibrotics",
    "Class2": "RNA",
    "Class3": "",
    "MOA": "Cystic fibrosis transmembrane conductance regulator expression stimulants",
    "RPDD Month": "11",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 1b",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Biogen",
    "COUNTRY": "US",
    "Indication": "Ornithine Transcarbamylase Deficiency",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Candidate": "ARCT-810",
    "Class1": "RNA",
    "Class2": "",
    "Class3": "",
    "MOA": "Ornithine carbamoyltransferase expression stimulants",
    "RPDD Month": "11",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 1b",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Biomarin",
    "COUNTRY": "SG",
    "Indication": "Neuroblastoma",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Candidate": "AUM302",
    "Class1": "2 ring heterocyclic compounds",
    "Class2": "Antineoplastics",
    "Class3": "Aza compounds",
    "MOA": "1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors; PIM3 protein inhibitors; Proto oncogene protein c pim 1 inhibitors; Proto-oncogene protein pim-2 inhibitors",
    "RPDD Month": "1",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Biomarin",
    "COUNTRY": "US",
    "Indication": "Dravet Syndrome",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Candidate": "BL-001",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "8",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 1",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "BioMarin",
    "COUNTRY": "UK",
    "Indication": "Dopamine Transporter Deficiency Syndrome",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Candidate": "BGT-DTDS",
    "Class1": "AAV",
    "Class2": "AAV2",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "8",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "bluebird Bio",
    "COUNTRY": "UK",
    "Indication": "Ornithine Transcarbamylase Deficiency",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Candidate": "BGT-OTCD",
    "Class1": "AAV",
    "Class2": "AAV2",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "8",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 1/2",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "bluebird Bio",
    "COUNTRY": "UK",
    "Indication": "Infantile Neuroaxonal Dystrophy",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Candidate": "BGT-INAD",
    "Class1": "AAV",
    "Class2": "AAV2",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "8",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Chiesi Farmaceutici S.p.A.",
    "COUNTRY": "UK",
    "Indication": "Niemann-Pick Disease Type C",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "Metabolic",
    "Candidate": "BGT-NPC",
    "Class1": "AAV",
    "Class2": "AAV9",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "8",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Day One",
    "COUNTRY": "JP",
    "Indication": "Netherton Syndrome",
    "TherapeuticArea1": "Dermatology",
    "TherapeuticArea2": "Genetic",
    "Candidate": "DS-2325",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "5",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 1",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Eiger BioPharmaceuticals",
    "COUNTRY": "US",
    "Indication": "Duchenne Muscular Dystrophy",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Candidate": "DYNE-251",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "5",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 1/2",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Enzyvant Therapeutics",
    "COUNTRY": "US",
    "Indication": "Duchenne Muscular Dystrophy",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Candidate": "EDG-5506",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "11",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 2",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Genentech",
    "COUNTRY": "US",
    "Indication": "Generalized Arterial Calcification of Infancy",
    "TherapeuticArea1": "Cardiovascular",
    "TherapeuticArea2": "",
    "Candidate": "ELT-001",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "10",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "GW Research",
    "COUNTRY": "US",
    "Indication": "Diffuse Intrinsic Pontine Glioma",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Candidate": "FLAG-003",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "2",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Ipsen Biopharmaceuticals",
    "COUNTRY": "KR",
    "Indication": "Sanfilippo Syndrome A",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "Metabolic",
    "Candidate": "GC1130A",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "1",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Italfarmaco S.p.A.",
    "COUNTRY": "US",
    "Indication": "Pitt-Hopkins Syndrome",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "Genetic",
    "Candidate": "Microbiota Transplant Therapy",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "8",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 2",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Krystal Biotech",
    "COUNTRY": "CN",
    "Indication": "Duchenne Muscular Dystrophy",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Candidate": "HG302",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "12",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Leadiant Bioscience",
    "COUNTRY": "CN",
    "Indication": "MECP2 duplication syndrome",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "Genetic",
    "Candidate": "HG204",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "8",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Marathon",
    "COUNTRY": "CN",
    "Indication": "RPE65 mutations inherited retinal disease",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "Genetic",
    "Candidate": "HG004",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "8",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 1",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Marinus Pharmaceuticals",
    "COUNTRY": "US",
    "Indication": "Pelizaeus-Merzbacher Disease",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "Genetic",
    "Candidate": "ION356",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "10",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Mirum Pharmaceuticals",
    "COUNTRY": "JP",
    "Indication": "Mucopolysaccharidosis Type II",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Candidate": "JR-141",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "1",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 3",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Neurocrine Biosciences",
    "COUNTRY": "US",
    "Indication": "Common Variable Immunodeficiency",
    "TherapeuticArea1": "Immunology",
    "TherapeuticArea2": "",
    "Candidate": "LCTG-001",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "8",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Novartis",
    "COUNTRY": "SP",
    "Indication": "Pediatric-Type Diffuse High Grade Glioma",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Candidate": "LAM561",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "9",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 1",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Novartis",
    "COUNTRY": "DE",
    "Indication": "Exstrophy-Epispadias Complex",
    "TherapeuticArea1": "Urology",
    "TherapeuticArea2": "",
    "Candidate": "Stem Cell Therapy",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "7",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Novimmune SA - Sobi",
    "COUNTRY": "NL",
    "Indication": "Intestinal Failure-Associated Liver Disease",
    "TherapeuticArea1": "Gastroenterology",
    "TherapeuticArea2": "Hepatology",
    "Candidate": "SEFA-6179",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "10",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 2a",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "NS Pharma",
    "COUNTRY": "US",
    "Indication": "Stargardt Disease",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "Genetic",
    "Candidate": "OCU410ST",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "4",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 1/2",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Orchard Therapeutics",
    "COUNTRY": "US",
    "Indication": "Adrenocortical Carcinoma",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Candidate": "OR-449",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "1",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Origin Biosciences",
    "COUNTRY": "CA",
    "Indication": "Duchenne Muscular Dystrophy",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Candidate": "SAT-3153",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "8",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Pharming",
    "COUNTRY": "CA",
    "Indication": "Hemophilia Type A",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Candidate": "Cell Pouch",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "11",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Prometic Biotherapeutics",
    "COUNTRY": "UK",
    "Indication": "Osteopetrosis",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "Metabolic",
    "Candidate": "SIS-101-ADO",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "5",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "PTC Therapeutics",
    "COUNTRY": "US",
    "Indication": "Neurofibromatosis type 1-associated Plexiform Neurofibromas",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "Neurology",
    "Candidate": "mirdametinib",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "11",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 2b",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Reata Pharmaceuticals",
    "COUNTRY": "JP",
    "Indication": "Ewing's Sarcoma",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Candidate": "TP-1287",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "4",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 1",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Regeneron",
    "COUNTRY": "UK",
    "Indication": "TUBB4A Leukodystrophy",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Candidate": "TBD",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "2",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Sarepta Therapeutics",
    "COUNTRY": "US",
    "Indication": "Phenylketonuria",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Candidate": "labafenogene marselecobac (SYNB1934)",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "1",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 3",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Sarepta Therapeutics",
    "COUNTRY": "JP",
    "Indication": "Congenital Thrombotic Thrombocytopenic Purpura",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Candidate": "ADZYNMA",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "8",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 3",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  },
  {
    "Company": "Sarepta Therapeutics",
    "COUNTRY": "JP",
    "Indication": "Fragile X Syndrome",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "Genetic",
    "Candidate": "zatolmilast",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "RPDD Month": "9",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "Link to Most Recent Trial": "https://patientlyiq.com/rpdprv-dash",
    "PDUFA": "",
    "Link to CrunchBase": "",
    "Approved": "",
    "FDA Marketing Approval Month": "",
    "FDA Marketing Approval Year": "",
    "Competitors": "",
    "PRV Issue Month": "",
    "PRV Issue Year": "",
    "Buyer": "",
    "Consideration": "",
    "Sale Year": "",
    "Redeemed for": ""
  }
]